Why Cornerstone OnDemand (CSOD) Stock Is Down Today

NEW YORK (TheStreet) -- Cornerstone OnDemand (CSOD) was falling 8.3% to $36.96 Thursday after missing analysts' estimates for earnings and revenue in the second quarter.

For the second quarter Cornerstone OnDemand reported a loss of -11 cents a share, missing the Capital IQ Consensus Estimate of a loss of -8 cents a share by 3 cents. Revenue grew 38.6% year-over-year to $61.46 million for the quarter. Analysts expected revenue of $63.57 million for the quarter.

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates CORNERSTONE ONDEMAND INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate CORNERSTONE ONDEMAND INC (CSOD) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk and feeble growth in its earnings per share."

CSOD ChartCSOD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Cornerstone OnDemand Stock Surges, Hires Bankers to Explore Strategic Options

Microsoft Is Helping LinkedIn Realize Its Untapped Potential

Analysts' Actions -- Express Scripts, Lions Gate, Qorvo, Whole Foods and More

As Broadcom Buys Brocade, Here Are Other Enterprise Technology Firms That Could Get Acquired Next

Analysts' Actions -- Tableau, Nucor, Pfizer, Square and More